BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 27614988)

  • 1. Multitargeted Kinase Inhibition in Metastatic Differentiated Radioiodine-Refractory Thyroid Cancer: A Look at New Therapeutic Options for a Rare Disease.
    Mischler K; Kneifel S; Cathomas R
    Oncol Res Treat; 2016; 39(9):548-52. PubMed ID: 27614988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 4. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
    Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
    Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
    Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
    Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
    [No Abstract]   [Full Text] [Related]  

  • 6. Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: A retrospective study.
    Iwasaki H; Yamazaki H; Takasaki H; Suganuma N; Sakai R; Nakayama H; Toda S; Masudo K
    Medicine (Baltimore); 2019 Oct; 98(42):e17588. PubMed ID: 31626129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
    Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 10. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.
    Narayanan S; Colevas AD
    Curr Treat Options Oncol; 2016 Jun; 17(6):30. PubMed ID: 27139457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
    Lindner C; Dierneder J; Pall G; Pirich C; Hoffmann M; Raderer M; Becherer A; Niederle B; Lipp R; Lind P; Gallowitsch H; Romeder F; Virgolini I
    Nuklearmedizin; 2015; 54(3):125-30. PubMed ID: 25421138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
    Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
    Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
    Yu J; Liu Z; Su Y; Peng X; Xie Y
    Clin Endocrinol (Oxf); 2024 Apr; 100(4):379-388. PubMed ID: 38351437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
    Yeung KT; Cohen EE
    Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
    Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
    Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
    [No Abstract]   [Full Text] [Related]  

  • 17. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
    Fleeman N; Houten R; Chaplin M; Beale S; Boland A; Dundar Y; Greenhalgh J; Duarte R; Shenoy A
    BMC Cancer; 2019 Dec; 19(1):1209. PubMed ID: 31830943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer.
    Ferrari SM; Elia G; Ragusa F; Paparo SR; Mazzi V; Miccoli M; Galdiero MR; Varricchi G; Foddis R; Guglielmi G; Spinelli C; La Motta C; Benvenga S; Antonelli A; Fallahi P
    Expert Opin Investig Drugs; 2021 Sep; 30(9):913-921. PubMed ID: 34428101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
    Hegazi M; Azadi A; Jain D; Redman R; Perez CA
    Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.
    Kish JK; Chatterjee D; Wan Y; Yu HT; Liassou D; Feinberg BA
    Adv Ther; 2020 Jun; 37(6):2841-2852. PubMed ID: 32382946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.